New pages

18:3518:35, 24 August 2026 FORZINITY- elamipretide hydrochloride injection (hist | edit) [25,769 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=mitochondrial cardiolipin binder. |indicationType=treatment |indication=Barth syndrome in adult and pediatric patients weighing at least 30 kg, to improve muscle strength. |adverseReactions=injection site reactions. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult====Barth Syndrome...")
18:2018:20, 24 August 2026 WAYRILZ- rilzabrutinib tablet, film coated (hist | edit) [35,307 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=Bruton's tyrosine kinase (BTK) inhibitor |indicationType=treatment |indication=adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. |adverseReactions=diarrhea, nausea, headache, abdominal pain, and COVID-19. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''<...")

08:3608:36, 22 August 2026 SAndbox: JAF MS ECG (hist | edit) [0 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Multiple sclerosis}} {{CMG}}; {{AE}} {{Fs}} ==Overview== An electrocardiogram (ECG) is '''not used to diagnose multiple sclerosis (MS)''', and there are no ECG findings that are specific or diagnostic for MS. The diagnosis of MS is established using clinical findings together with appropriate paraclinical evidence, including MRI and, when appropriate, cerebrospinal fluid (CSF) biomarkers, according to the 2024 revision...")

20:2420:24, 20 August 2026 Sandbox:JAF (hist | edit) [21,647 bytes] Julinka Auta Fernandes (talk | contribs) (Created page with "__NOTOC__ {{Template:Multiple sclerosis}} {{CMG}}; {{AE}} {{Fs}} ==Overview== The symptoms of multiple sclerosis (MS) are variable and may involve vision, sensory function, motor function, coordination, cognitive impairment, mood, bowel and bladder function, sexual dysfunction, sleep, and fatigue. Common manifestations include Fatigue, mood pro...")
04:5704:57, 20 August 2026 Templete:ANG (hist | edit) [66 bytes] Aiden Nguyen (talk | contribs) (Created page with "Aiden Nguyen[mailto:aidennguyen7@gmail.com]")

23:1223:12, 15 August 2026 BRINSUPRI- brensocatib tablet (hist | edit) [33,398 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Brensocatib |aOrAn=a |drugClass=dipeptidyl peptidase 1 (DPP1) inhibitor |indicationType=treatment |indication=non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older |adverseReactions=upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, hypertension. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBo...")
22:3722:37, 15 August 2026 DAWNZERA- donidalorsen injection, solution (hist | edit) [49,127 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Donidalorsen |aOrAn=a |drugClass=prekallikrein directed antisense oligonucleotide |indicationType=prophylaxis |indication=attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. |adverseReactions=injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort. |blackBoxWarningTitle='''<span style="color:#FF00...")
22:0322:03, 15 August 2026 HERNEXEOS- zongertinib tablet, film coated (hist | edit) [41,832 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Zongertinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. |adverseReactions=diarrhea, rash, hepatotoxicity, fatigue, nausea, musculoskelet...")

16:3216:32, 14 August 2026 Sandbox: HAM (hist | edit) [14,417 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{SAI}} {{Tension headache}} ==Tension type headache medical therapy== Medical management of tension-type headache (TTH) consists of acute treatment with simple analgesics, preventive therapy for frequent or disabling headache, evidence-based behavioral interventions, and prevention of medication-overuse headache (MOH). Current evidence supports ibuprofen or acetaminophen as first-line acute therapy and amitriptyline as the b...")
06:2806:28, 14 August 2026 Vascular cognitive impairment and dementia historical perspective (hist | edit) [9,830 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Vascular cognitive impairment and dementia}} '''To view the main page click here.''' {{CMG}}; {{AE}} {{HAM}} ==Historical Perspective== ===Overview=== The concept of '''vascular cognitive impairment and dementia (VCID)''' has evolved through three broad eras: 19th-century recognition of discrete vascular brain lesions (Marie's ''état lacunaire''; Binswanger's subcortical white matter disease), a mid-20th-century "arteriosclerotic dementia" h...")
04:2404:24, 14 August 2026 Vascular cognitive impairment and dementia Overview (hist | edit) [17,040 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Vascular cognitive impairment and dementia}} '''To view the main page click here.''' {{CMG}}; {{AE}} HAM ==Overview== '''Vascular cognitive impairment and dementia (VCID)''' is cognitive impairment attributable predominantly to cerebrovascular disease, spanning a spectrum from mild vascular cognitive impairment (VCI) to vascular dementia (VaD), its most severe form.<ref name="Sachdev2026">{{cite journal...")
02:0202:02, 14 August 2026 Vascular cognitive impairment and dementia (hist | edit) [2,036 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Vascular cognitive impairment and dementia}} '''To view the main page click here.''' {{CMG}}; {{AE}} Person 1, Person 2, Your Name ==Overview== ==Historical Perspective== ==Classification== ==Pathophysiology== ==Causes== ==Type pa...")

15:5215:52, 13 August 2026 MODEYSO- dordaviprone capsule (hist | edit) [45,937 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Dordaviprone |aOrAn=a |drugClass=protease activator |indicationType=treatment |indication=adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. |adverseReactions=fatigue, headache, vomiting, nausea, and musculoskeletal pain. |blackBoxWarningTitle='''TITLE...")
15:3315:33, 13 August 2026 VIZZ- aceclidine solution/ drops (hist | edit) [15,742 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Aceclidine |aOrAn=a |drugClass=cholinergic muscarinic agonist |indicationType=treatment |indication=presbyopia in adults. |adverseReactions=instillation site irritation, dim vision, and headache. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult====Presbyopia=== ====FDA-Labeled Indication...")
12:5612:56, 13 August 2026 PALSONIFY- paltusotine tablet, film coated (hist | edit) [38,274 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Paltusotine |aOrAn=a |drugClass=somatostatin receptor agonist |indicationType=treatment |indication=adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. |adverseReactions=diarrhea, abdominal pain, nausea, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis. |blackBoxWarningTitle='''<span...")

13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy case studies (hist | edit) [25 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy future or investigational therapies (hist | edit) [16,766 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy cost-effectiveness of therapy (hist | edit) [14,005 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2613:26, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy follow-up and surveillance (hist | edit) [22,203 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2413:24, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy comparative therapies (hist | edit) [22,822 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2413:24, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy outcomes and prognosis (hist | edit) [21,364 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2413:24, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy periprocedural complications (hist | edit) [20,563 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy procedural technique and intraprocedural imaging (hist | edit) [20,797 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy pre-procedural imaging and assessment (hist | edit) [14,889 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy indications and contraindications (hist | edit) [18,948 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy pathophysiology of gradient reduction (hist | edit) [18,106 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2313:23, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy patient and anatomic selection (hist | edit) [14,891 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2213:22, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy historical perspective (hist | edit) [20,211 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
13:2213:22, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy overview (hist | edit) [10,219 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
11:4611:46, 5 August 2026 Alcohol septal ablation for hypertrophic obstructive cardiomyopathy (hist | edit) [2,106 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{xyz}} '''To view the main page click here.''' {{CMG}}; {{AE}} {{Nehal}} ==Overview== ==Historical Perspective== ==Patient and Anatomic Selection== ==Pathophysiology of Gradient Reduction== ==Type page name here Indications a...")
11:1411:14, 5 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Future Therapies (hist | edit) [20,286 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
11:0911:09, 5 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Cost-Effectiveness (hist | edit) [8,313 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}} __NOTOC__ ==Cost-Effectiveness== Economic evidence for transcatheter edge-to-edge repair (TEER) in heart failure with reduced ejection fraction and secondary mitral regurgitation is derived predominantly from COAPT-based analyses comparing TEER plus guideline-directed medical therapy (GDMT) with GDMT alone. The results are model-based, payer-specific, and dependent on patient selection, device cost, hospitalization reduction, an...")

19:1919:19, 3 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Follow-Up and Surveillance (hist | edit) [51,678 bytes] Nehal Eid (talk | contribs) (Created page with "{{CMG}}; {{AE}} {{Nehal}}")
19:1019:10, 3 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) natural history, complications and prognosis (hist | edit) [30,115 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ ==Natural history, complications, and prognosis== ===Natural history during guideline-directed medical therapy=== Ventricular secondary mitral regurgitation (SMR) in heart failure with reduced ejection fraction (HFrEF) is a dynamic lesion whose severity may change substantially after optimization of guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT). In a prospective cohort of 2,254 ambulatory patients with...")

12:3612:36, 2 August 2026 Medical therapy (GDMT optimization before and after M-TEER) (hist | edit) [35 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Nehal}}")
12:3612:36, 2 August 2026 Other Imaging Findings / Other Diagnostic Studies (hist | edit) [35 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Nehal}}")
12:3512:35, 2 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) Treatment (hist | edit) [24,928 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Nehal}}")
12:3512:35, 2 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) imaging and assessment (hist | edit) [30,638 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Nehal}}")
12:3312:33, 2 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) procedural Technique and intraprocedural Imaging (hist | edit) [40,124 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Nehal}}")
12:3312:33, 2 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) indications and contraindications (hist | edit) [27,602 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} {{Nehal}}")
11:5711:57, 2 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) pathophysiology (hist | edit) [29,259 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ ==Pathophysiology== ===Mechanism of ventricular secondary mitral regurgitation=== Ventricular secondary mitral regurgitation (vSMR) results when structurally normal mitral leaflets fail to coapt because of left ventricular (LV) remodeling. The central mechanical abnormality is an imbalance between '''tethering forces'''—apical and lateral papillary-muscle displacement, annular dilation and flattening, and increas...")
00:1600:16, 2 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) classification (hist | edit) [17,513 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ ==Classification== ===Classification framework=== Classification of mitral regurgitation (MR) in patients considered for mitral transcatheter edge-to-edge repair (M-TEER) requires three complementary descriptions: * MR etiology and mechanism * MR severity nomenclature * The class of transcatheter intervention and the standardized classification of its result M-TEER is the procedural class; MitraClip and PASCAL are device platforms within that class....")

23:4023:40, 1 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) historical perspective (hist | edit) [27,689 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ ==Historical Perspective== ===Surgical origin and early transcatheter development=== Mitral transcatheter edge-to-edge repair (M-TEER) evolved from the surgical '''Alfieri edge-to-edge repair''', developed in the 1990s. Approximation of the middle portions of the anterior and posterior mitral leaflets created a double-orifice valve; transcatheter systems subsequently reproduced this principle through percutaneous leaflet grasping.<ref name="maisano2011">{...") Tag: Visual edit: Switched
22:3422:34, 1 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) overview (hist | edit) [24,419 bytes] Nehal Eid (talk | contribs) (Created page with "===Definition and principle=== '''Mitral transcatheter edge-to-edge repair (M-TEER)''' is a transseptal, catheter-based therapy that approximates the anterior and posterior mitral valve leaflets, restores leaflet coaptation, and creates a double-orifice valve to reduce mitral regurgitation. M-TEER is the procedural term; MitraClip and PASCAL are device platforms.<ref name="ogara2020">{{cite journal |author=O'Gara PT, Mack MJ |title=Secondary Mitral Regurgitation...")
19:1719:17, 1 August 2026 Percutaneous mitral repair as treatment in HFrEF (MitraClip/TEER) (hist | edit) [1,639 bytes] Nehal Eid (talk | contribs) (Created page with "__NOTOC__ {{xyz}} '''To view the main page click here.''' {{CMG}}; {{AE}} Person 1, Person 2, Your Name ==Overview== ==Historical Perspective== ==Classification== ==Pathophysiology== ==Causes== ==Type page name here differential diagnosis|Dif...")

22:0422:04, 29 July 2026 Mitral stenosis transcatheter therapy (hist | edit) [23,508 bytes] Sudarshan Srivats (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; '''Associate Editor-In-Chief:''' {{SUD}}; {{Sara.Zand}} Mohammed A. Sbeih, M.D. [mailto:msbeih@wikidoc.org]; Joanna J. Wykrzykowska, M.D. {{Mitral stenosis}} {{SK}} Balloon mitral valvuloplasty, PMBC, percutaneous mitral balloon valvotomy, percutaneous mitral balloon valvuloplasty, PMBV, mitral valvuloplasty, percutaneous mitral valvuloplasty, PMC, percutaneous mitral commissurotomy ==Overview== Percutaneous mitral balloon v...")
14:0814:08, 29 July 2026 Thoracic Endovascular Aortic Repair (TEVAR) (hist | edit) [31,272 bytes] Anum Ijaz (talk | contribs) (Created page with " {{CMG}} {{AE}} {{AIJ}} == Overview == Thoracic endovascular aortic repair ('''TEVAR''') is a catheter-based technique for treatment of pathology involving the descending thoracic aorta, including thoracic aortic aneurysm (TAA), complicated and select uncomplicated type B aortic dissection (TBAD), blunt traumatic aortic injury (BTAI), penetrating aortic ulcer, and intramural hematoma. First performed in 1994 and FDA-approved for descending TAA in 2005, TEVAR...") Tag: Visual edit

New pages

24 August 2026

22 August 2026

20 August 2026

15 August 2026

14 August 2026

13 August 2026

5 August 2026

3 August 2026

2 August 2026

1 August 2026

29 July 2026

Navigation menu

Search